Format

Send to

Choose Destination
Best Pract Res Clin Haematol. 2014 Jun;27(2):155-64. doi: 10.1016/j.beha.2014.07.008. Epub 2014 Jul 18.

Prognostication in MF: from CBC to cytogenetics to molecular markers.

Author information

1
Washington University School of Medicine, Division of Hematology, 660 S. Euclid Ave, Campus Box 8056, St. Louis, MO 63110, USA. Electronic address: azhou@dom.wustl.edu.
2
Washington University School of Medicine, Division of Hematology, 660 S. Euclid Ave, Campus Box 8125, St. Louis, MO 63110, USA. Electronic address: stoh@dom.wustl.edu.

Abstract

Myelofibrosis (MF) is a clonal stem cell disorder characterized by ineffective erythropoiesis and extramedullary hematopoiesis leading to progressive bone marrow failure, severe anemia, constitutional symptoms, hepatosplenomegaly, and thrombosis. MF can arise following a history of polycythemia vera (PV) or essential thrombocythemia (ET), or can present de novo as primary myelofibrosis (PMF). The disease course is variable with median survival ranging from months to years. Clinical and biological features such as advanced age, leukocytosis, anemia, transfusion dependence, and elevated inflammatory markers can impact prognosis in patients with PMF. Cytogenetic abnormalities and molecular markers such as JAK2 V617F, ASXL1, and CALR mutations have also been identified as prognostic variables. Several different scoring systems have been developed based on these prognostic factors. In this review, we will discuss the clinical, biological, molecular, and cytogenetic prognostic factors that have been identified in PMF, and the current prognostic models that have been developed to guide treatment decisions.

KEYWORDS:

myelofibrosis; prognosis; survival

PMID:
25189726
DOI:
10.1016/j.beha.2014.07.008
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center